For gene therapy, increased cargo-capacity accommodates large therapeutically relevant genes such as DNA-PKcs for X-linked severe combined immune deficiency [37] or factor VIII for hemophilia A [38]. This evidence concerns the gene PRKDC and hemophilia A.